The FDA said cardiovascular devices make up the largest number of technologies accepted into the Breakthrough Devices Program, and several are on the list of the first 50 in the program to gain market clearance.

Steve Cashman, Caption Health’s CEO, described the partnership as “an ideal coupling of patient-centric services.”

The study's authors explored data from 35 patients who received the TricValve Transcatheter Bicaval Valves System. All patients presented with severe tricuspid regurgitation.

The new analysis focused on transcatheter edge-to-edge repair and left atrial appendage occlusion procedures.

Charles Davidson, MD, clinical chief of cardiology and medical director of the Bluhm Cardiovascular Institute, Northwestern University, explains what hospitals need to consider when starting a new structural heart program. 

Artificial intelligence vendor DiA has emerged as a key third-party provider of AI to larger imaging vendors.

It has been a busy few weeks for the FDA, with plenty of big-name approvals and recalls making the news, but there have also been some other big announcements related to solutions receiving FDA clearance. 

There were several point-of-care ultrasound (POCUS) systems on display by vendors at ACC 2022. Here are two of them.